S König1, C W Hirneiß2. 1. Augenklinik, Klinikum der Universität München, Ludwig-Maximilians-Universität, Mathildenstr. 8, 80336, München, Deutschland. 2. Augenklinik, Klinikum der Universität München, Ludwig-Maximilians-Universität, Mathildenstr. 8, 80336, München, Deutschland. christoph.hirneiss@med.uni-muenchen.de.
Abstract
BACKGROUND: The STARflo Glaucoma Device (iSTAR Medical, Wavre, Belgium) offers a new approach to bleb-free filtering surgery in which the intraocular pressure (IOP) is lowered by supporting outflow of the aqueous humor into the suprachoroidal space. MATERIALS AND METHODS: On the basis of a case series of 9 patients with open-angle glaucoma (OAG) unmanageable by drug-based treatment, intra- and postoperative experiences with the implant are presented. The implant, the implantation procedure, and the first results 6 months postoperatively are described. RESULTS: No intraoperative complications were observed. Postoperative complications such as increased astigmatism or ocular hypotony were rare and transient. After 6 months there was an IOP reduction from 29.1 mm Hg ± 6.1 mm Hg with 2.7 ± 1.1 local IOP-lowering medications to 16.1 ± 4.1 mm Hg (IOP reduction of 44.7%) with additional 2.0 ± 0.8 local IOP-lowering medications. DISCUSSION: The new STARflo Glaucoma Device shows promising results in reducing the IOP of medically uncontrolled OAG. Further investigations concerning the long-time efficacy of the implant and additional IOP-lowering medication are still ongoing.
BACKGROUND: The STARflo Glaucoma Device (iSTAR Medical, Wavre, Belgium) offers a new approach to bleb-free filtering surgery in which the intraocular pressure (IOP) is lowered by supporting outflow of the aqueous humor into the suprachoroidal space. MATERIALS AND METHODS: On the basis of a case series of 9 patients with open-angle glaucoma (OAG) unmanageable by drug-based treatment, intra- and postoperative experiences with the implant are presented. The implant, the implantation procedure, and the first results 6 months postoperatively are described. RESULTS: No intraoperative complications were observed. Postoperative complications such as increased astigmatism or ocular hypotony were rare and transient. After 6 months there was an IOP reduction from 29.1 mm Hg ± 6.1 mm Hg with 2.7 ± 1.1 local IOP-lowering medications to 16.1 ± 4.1 mm Hg (IOP reduction of 44.7%) with additional 2.0 ± 0.8 local IOP-lowering medications. DISCUSSION: The new STARflo Glaucoma Device shows promising results in reducing the IOP of medically uncontrolled OAG. Further investigations concerning the long-time efficacy of the implant and additional IOP-lowering medication are still ongoing.
Authors: Lauran R Madden; Derek J Mortisen; Eric M Sussman; Sarah K Dupras; James A Fugate; Janet L Cuy; Kip D Hauch; Michael A Laflamme; Charles E Murry; Buddy D Ratner Journal: Proc Natl Acad Sci U S A Date: 2010-08-09 Impact factor: 11.205
Authors: Steven Vold; Iqbal Ike K Ahmed; E Randy Craven; Cynthia Mattox; Robert Stamper; Mark Packer; Reay H Brown; Tsontcho Ianchulev Journal: Ophthalmology Date: 2016-08-06 Impact factor: 12.079
Authors: S Schrittenlocher; A Doulis; K R Koch; A Lappas; L Altay; A-M Lentzsch; C Cursiefen; B Bachmann; V Prokosch-Willing; T Dietlein Journal: Ophthalmologe Date: 2021-04-21 Impact factor: 1.059